ImmunologyDrug intelligence

Dupixent

Dupilumab

IL-4 receptor alpha antagonist. Developed by Sanofi. Clinical, regulatory, and source evidence are connected below.

Company: Sanofi
Target / MOA: IL-4Rα · IL4R
Aliases: Dupixent · REGN668 · SAR231893

Signals: 24
Clinical trials: 20
Approvals: 1
Evidence sources: 24

Latest signals

What changed

The three most recent source-backed changes linked to this drug.

clinical trialApr 2, 2026ClinicalTrials.gov

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Phase 3 · RECRUITING · AbbVie

clinical trialApr 1, 2026ClinicalTrials.gov

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Phase 3 · RECRUITING · AbbVie

clinical trialMar 31, 2026ClinicalTrials.gov

A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers

Phase 1 · NOT_YET_RECRUITING · Innovent Biologics (Suzhou) Co. Ltd.

Clinical trials

Key active studies

A focused view of recently updated studies · 20 linked records.

Phase 3RECRUITINGNCT06389136

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

AbbVie · Updated Apr 2, 2026

Phase 3RECRUITINGNCT06461897

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

AbbVie · Updated Apr 1, 2026

Phase 1NOT YET RECRUITINGNCT07502534

A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers

Innovent Biologics (Suzhou) Co. Ltd. · Updated Mar 31, 2026

Phase 1ACTIVE NOT RECRUITINGNCT07027527

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics, Inc. · Updated Mar 25, 2026

Phase 4RECRUITINGNCT07053423

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

Sanofi · Updated Mar 24, 2026

N/AACTIVE NOT RECRUITINGNCT05857228

Viral and Epigenetic Influences in CRSwNP

Centre hospitalier de l'Université de Montréal (CHUM) · Updated Mar 20, 2026

Regulatory timeline

Approvals and agency activity

Verified regulatory records in reverse chronological order.

Mar 24, 2026 ·

Dupixent®(dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Mar 24, 2026 ·

2026 03 24 06 00 00 3260948

Mar 28, 2017 · FDA

DUPIXENT

Related intelligence

Connected drugs

Records connected through the current intelligence graph.

Source evidence

Where this profile comes from

Facts link back to original registries, regulators, labels, and publishers. Counts change as source records update.

ClinicalTrials.govofficial · Latest Apr 2, 202620 FDAofficial · Latest Mar 28, 20171

Professional referenceThis profile summarizes linked public evidence. It is not medical, legal, regulatory, or investment advice. Verify decisions against original sources.